Sartorius Stedim Biotech S.A. (SDMHF)
USD 201.5
(0.0%)
USD 201.5
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 7.75 Billion EUR | 53.03% |
| 2022 | 5.06 Billion EUR | 28.2% |
| 2021 | 3.95 Billion EUR | 28.73% |
| 2020 | 3.06 Billion EUR | 68.61% |
| 2019 | 1.82 Billion EUR | 15.84% |
| 2018 | 1.57 Billion EUR | 11.93% |
| 2017 | 1.4 Billion EUR | 17.4% |
| 2016 | 1.19 Billion EUR | 12.17% |
| 2015 | 1.06 Billion EUR | 17.58% |
| 2014 | 906.75 Million EUR | 4.08% |
| 2013 | 871.22 Million EUR | 9.74% |
| 2012 | 793.86 Million EUR | 10.16% |
| 2011 | 720.66 Million EUR | 9.8% |
| 2010 | 656.33 Million EUR | -1.73% |
| 2009 | 667.85 Million EUR | 2.38% |
| 2008 | 652.34 Million EUR | 1.81% |
| 2007 | 640.72 Million EUR | 69.8% |
| 2006 | 377.34 Million EUR | 4.09% |
| 2005 | 362.52 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 7.99 Billion EUR | -0.88% |
| 2024 Q1 | 8.43 Billion EUR | 8.87% |
| 2024 Q2 | 8.06 Billion EUR | -4.39% |
| 2023 Q1 | 5.09 Billion EUR | 0.62% |
| 2023 Q2 | 5.18 Billion EUR | 1.78% |
| 2023 Q3 | 7.95 Billion EUR | 53.43% |
| 2023 Q4 | 7.75 Billion EUR | -2.6% |
| 2023 FY | 7.75 Billion EUR | 53.03% |
| 2022 Q1 | 4.15 Billion EUR | 5.25% |
| 2022 FY | 5.06 Billion EUR | 28.2% |
| 2022 Q2 | 4.37 Billion EUR | 5.2% |
| 2022 Q3 | 5.09 Billion EUR | 16.5% |
| 2022 Q4 | 5.06 Billion EUR | -0.62% |
| 2021 Q3 | 3.97 Billion EUR | 12.9% |
| 2021 Q4 | 3.95 Billion EUR | -0.63% |
| 2021 FY | 3.95 Billion EUR | 28.73% |
| 2021 Q1 | 3.31 Billion EUR | 7.94% |
| 2021 Q2 | 3.52 Billion EUR | 6.31% |
| 2020 Q2 | 2.22 Billion EUR | 17.34% |
| 2020 Q1 | 1.89 Billion EUR | 4.12% |
| 2020 FY | 3.06 Billion EUR | 68.61% |
| 2020 Q4 | 3.06 Billion EUR | 29.97% |
| 2020 Q3 | 2.36 Billion EUR | 6.18% |
| 2019 Q4 | 1.82 Billion EUR | 2.74% |
| 2019 FY | 1.82 Billion EUR | 15.84% |
| 2019 Q2 | 1.69 Billion EUR | 2.01% |
| 2019 Q3 | 1.77 Billion EUR | 4.61% |
| 2019 Q1 | 1.66 Billion EUR | 5.66% |
| 2018 Q3 | 1.58 Billion EUR | 5.32% |
| 2018 Q1 | 1.45 Billion EUR | 3.8% |
| 2018 Q4 | 1.57 Billion EUR | -0.86% |
| 2018 FY | 1.57 Billion EUR | 11.93% |
| 2018 Q2 | 1.5 Billion EUR | 3.28% |
| 2017 Q4 | 1.4 Billion EUR | 2.87% |
| 2017 FY | 1.4 Billion EUR | 17.4% |
| 2017 Q1 | 1.3 Billion EUR | 9.11% |
| 2017 Q2 | 1.34 Billion EUR | 2.83% |
| 2017 Q3 | 1.36 Billion EUR | 1.72% |
| 2016 FY | 1.19 Billion EUR | 12.17% |
| 2016 Q3 | 1.18 Billion EUR | 3.92% |
| 2016 Q2 | 1.14 Billion EUR | 4.02% |
| 2016 Q1 | 1.09 Billion EUR | 3.14% |
| 2016 Q4 | 1.19 Billion EUR | 0.61% |
| 2015 Q4 | 1.06 Billion EUR | 0.73% |
| 2015 Q3 | 1.05 Billion EUR | 4.14% |
| 2015 Q2 | 1.01 Billion EUR | 4.65% |
| 2015 Q1 | 971.1 Million EUR | 7.03% |
| 2015 FY | 1.06 Billion EUR | 17.58% |
| 2014 FY | 906.75 Million EUR | 4.08% |
| 2014 Q4 | 907.34 Million EUR | -2.48% |
| 2014 Q3 | 930.4 Million EUR | 2.46% |
| 2014 Q2 | 908.1 Million EUR | 0.87% |
| 2014 Q1 | 900.3 Million EUR | 3.08% |
| 2013 FY | 871.22 Million EUR | 9.74% |
| 2013 Q4 | 873.41 Million EUR | 8.14% |
| 2013 Q2 | 814.9 Million EUR | 0.0% |
| 2013 Q3 | 807.7 Million EUR | -0.88% |
| 2012 FY | 793.86 Million EUR | 10.16% |
| 2012 Q2 | 763.3 Million EUR | 0.0% |
| 2011 Q2 | 687.8 Million EUR | 0.0% |
| 2011 FY | 720.66 Million EUR | 9.8% |
| 2010 Q2 | 660.3 Million EUR | 0.0% |
| 2010 FY | 656.33 Million EUR | -1.73% |
| 2009 FY | 667.85 Million EUR | 2.38% |
| 2009 Q4 | 667.85 Million EUR | 0.0% |
| 2008 FY | 652.34 Million EUR | 1.81% |
| 2007 FY | 640.72 Million EUR | 69.8% |
| 2006 FY | 377.34 Million EUR | 4.09% |
| 2005 FY | 362.52 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| American Medical Technologies Inc. | 1.83 Million USD | -421627.256% |
| Ansell Limited | 3.23 Billion USD | -139.503% |
| Ansell Limited | 3.24 Billion USD | -139.055% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 488.98 Million USD | -1485.231% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 300.36 Thousand USD | -2580652.559% |
| Psykey, Inc. | 1.72 Million USD | -448654.168% |
| ConvaTec Group Plc | 3.7 Billion USD | -109.025% |
| ConvaTec Group Plc | 3.71 Billion USD | -108.73% |
| Encision Inc. | 3.81 Million USD | -203315.841% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | - USD | -Infinity% |
| Innovative MedTech Inc. | 651.88 Thousand USD | -1189012.737% |
| LifePoint, Inc. | 8.8 Million USD | -87894.659% |
| Medite Cancer Diagnostics, Inc. | 15.95 Million USD | -48481.098% |
| Paradigm Medical Industries, Inc. | 895 Thousand USD | -866000.559% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | 5.48 Million USD | -141119.517% |
| Reflect Scientific, Inc. | 2.66 Million USD | -290341.429% |
| SmileDirectClub, Inc. | 597.06 Million USD | -1198.288% |
| Sector 10, Inc. | 1000.00 USD | -775159900.0% |
| Shandong Weigao Group Medical Polymer Company Limited | 4.74 Billion USD | -63.322% |
| SheerVision, Inc. | 837.56 Thousand USD | -925392.35% |
| United Health Products, Inc. | 284.64 Thousand USD | -2723170.904% |
| Vasamed, Inc. | 1.6 Million USD | -484301.432% |
| Wearable Health Solutions, Inc. | 223.17 Thousand USD | -3473259.233% |
| Yubo International Biotech Limited | 2.34 Million USD | -329958.832% |